Music activates multiple parts of the brain. For people with MS, a choir is exploring what singing together can offer.
Roche’s phase III FENtrepid study of fenebrutinib meets its primary endpoint of non-inferiority compared to Ocrevus in reducing disability progression in patients with PPMS ...
Roche has shared the numbers behind its phase 3 win in primary progressive multiple sclerosis (PPMS), linking its BTK ...
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of ...
Roche Holdings AG RHHBY on Monday shared new late-breaking data from the Phase 3 FENtrepid study of the investigational ...
After up to three years on GA Depot, most people with PPMS have not experienced any disability progression, according to new ...
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton's tyrosine kinase (BTK ...
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in reduc ...
Everyday Health on MSN
Travel tips for multiple sclerosis
Discover how to plan for travel with multiple sclerosis. Get tips on managing fatigue, mobility, heat sensitivity, choosing destinations, and what to bring for ease.
The investigational therapy fenebrutinib was as effective as Ocrevus for reducing disability progression in people with PPMS, a trial showed.
Swiss pharma giant Roche has announced new late-breaking data from the Phase III FENtrepid study showing the investigational ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results